Tagrisso and Bone pain aggravated - a phase IV clinical study of FDA data

Summary:

Bone pain aggravated is reported as a side effect among people who take Tagrisso (osimertinib mesylate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Iressa, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Bone pain aggravated when taking Tagrisso. It is created by eHealthMe based on reports of 19,861 people who have side effects when taking Tagrisso from the FDA, and is updated regularly.

What is Tagrisso?

Tagrisso has active ingredients of osimertinib mesylate. eHealthMe is studying from 19,890 Tagrisso users. Check the latest studies of Tagrisso.

What is Bone pain aggravated?

Bone pain aggravated is found to be associated with 1,422 drugs and 425 conditions by eHealthMe. Check the latest studies of Bone pain aggravated.

On Jul, 17, 2026

19,861 people reported to have side effects when taking Tagrisso.
Among them, 46 people (0.23%) have Bone pain aggravated.

Could Tagrisso cause Bone pain aggravated?

Among these 46 people:

How long have people been on Tagrisso when they have Bone pain aggravated? *

What is the gender of people who have Bone pain aggravated when taking Tagrisso? *

female: 73.91 %
male: 26.09 %

What is the age of people who have Bone pain aggravated when taking Tagrisso? *

What are other drugs people take besides Tagrisso? *

What are other side effects people have besides Bone pain aggravated? *

Fatigue (feeling of tiredness): 10 people, 21.74%
Malignant Neoplasm Progression (cancer tumour came back): 10 people, 21.74%
Dyspnea (difficult or laboured breathing): 8 people, 17.39%
Diarrhea: 8 people, 17.39%
Rashes (redness): 8 people, 17.39%
Cough: 7 people, 15.22%
Dry Mouth: 7 people, 15.22%
Back Pain: 7 people, 15.22%
Weakness: 6 people, 13.04%
Pleural Effusion (water on the lungs): 6 people, 13.04%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 11 people, 23.91%
Lung Cancer - Non-Small Cell (lung cancer): 8 people, 17.39%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 7 people, 15.22%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 6 people, 13.04%
Non-Small Cell Lung Cancer Stage Iv: 4 people, 8.70%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 8.70%
Pain: 3 people, 6.52%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 4.35%
High Blood Pressure: 2 people, 4.35%
Metastases To Central Nervous System (cancer spreads to central nervous system): 2 people, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Tagrisso and have Bone pain aggravated?

- Check whether Bone pain aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tagrisso:

Tagrisso (19,890 reports)

Browse all side effects of Tagrisso:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone pain aggravated:

Bone pain aggravated (1,422 drugs)

Browse all the conditions that are associated with Bone pain aggravated:

Bone pain aggravated (425 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on osimertinib mesylate (the active ingredients of Tagrisso) and Tagrisso (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.